Synageva Reports Closing of Targeted Enrollment in Phase 1/2 Trial with SBC-103 for Mucopholysaccharidosis IIIB
June 04, 2015 at 16:06 PM EDT
Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, today announced ...